Atezolizumab Lung Toxicity: Importance of Combination Treatment On The Edge of Life, A Case Report

Basit Öğe Kaydı
dc.authoridKoç, Aysu Sinem/0000-0001-5402-6730
dc.authoridCan, Orcun/0000-0001-5053-7023
dc.authoridKOBAK, SENOL/0000-0001-8270-640X
dc.authorwosidKoç, Aysu Sinem/GQH-6513-2022
dc.contributor.authorKoc, Aysu Sinem
dc.contributor.authorCan, Orcun
dc.contributor.authorKobak, Senol
dc.date.accessioned2024-05-19T14:39:10Z
dc.date.available2024-05-19T14:39:10Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBackground: Lung cancer is one of the most common and mortal cancers worldwide. According to pathological and clinical groups, treatments vary, and a tailored approach is considered. Adjuvant therapies, such as chemotherapy, radiation, and immune checkpoint inhibitors (ICI), are recommended by recent guidelines for patients with locally advanced cancer. Objective: This study aimed to report the case of a patient with stage 2B squamous cell lung carcinoma who was managed for pulmonary toxicity after receiving adjuvant chemotherapy and atezolizumab treatment. Case Report: A 66-year-old male patient received chemotherapy and immunotherapy after surgery for squamous cell lung cancer. A diagnosis of atezolizumab-associated pneumonitis was made using laboratory tests and imaging due to the patient's worsening dyspnea after treatment. Due to the patient's rapid progression, pulse steroid and MMF therapy were administered concurrently. When Klebsiella pneumoniae growth was detected in the sputum culture during the follow-up, IVIg was used to supplement the medication. The patient showed significant clinical and radiological improvement. Conclusion: In this study, we present an atezolizumab-induced pneumonitis case of a squamous cell lung cancer patient. It may be life-saving not to avoid aggressive treatment approaches by combining the steps of guideline recommendations in patients with rapidly progressive pneumonitis.en_US
dc.identifier.doi10.2174/1574886318666230824155341
dc.identifier.issn1574-8863
dc.identifier.issn2212-3911
dc.identifier.pmid37622710en_US
dc.identifier.urihttps://doi.org10.2174/1574886318666230824155341
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4716
dc.identifier.wosWOS:001169767000001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherBentham Science Publen_US
dc.relation.ispartofCurrent Drug Safetyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectAtezolizumaben_US
dc.subjectCase Reporten_US
dc.subjectCheckpoint Inhibitorsen_US
dc.subjectIvigen_US
dc.subjectLung Canceren_US
dc.subjectMycophenolate Mofetilen_US
dc.subjectPneumonitisen_US
dc.titleAtezolizumab Lung Toxicity: Importance of Combination Treatment On The Edge of Life, A Case Reporten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu